Chronically high blood glucose (hyperglycemia) leads to diabetes, fatty liver disease, and cardiovascular disease. Obesity is a major risk factor for hyperglycemia, but the underlying mechanism is unknown. Here we show that a high fat diet (HFD) in mice causes early loss of expression of the glycolytic enzyme Hexokinase 2 (HK2) 5 specifically in adipose tissue. Adipose-specific knockout of Hk2 caused enhanced gluconeogenesis and lipogenesis in liver, a condition known as selective insulin resistance, leading to glucose intolerance. Furthermore, we observed reduced hexokinase activity in adipose tissue of obese and diabetic patients, and identified a loss-of-function mutation in the hk2 gene of naturally hyperglycemic Mexican cavefish. 10 Mechanistically, HFD in mice led to loss of HK2 by inhibiting translation of Hk2 mRNA.
Abstract:
Chronically high blood glucose (hyperglycemia) leads to diabetes, fatty liver disease, and cardiovascular disease. Obesity is a major risk factor for hyperglycemia, but the underlying mechanism is unknown. Here we show that a high fat diet (HFD) in mice causes early loss of expression of the glycolytic enzyme Hexokinase 2 (HK2) 5 specifically in adipose tissue. Adipose-specific knockout of Hk2 caused enhanced gluconeogenesis and lipogenesis in liver, a condition known as selective insulin resistance, leading to glucose intolerance. Furthermore, we observed reduced hexokinase activity in adipose tissue of obese and diabetic patients, and identified a loss-of-function mutation in the hk2 gene of naturally hyperglycemic Mexican cavefish. 10 Mechanistically, HFD in mice led to loss of HK2 by inhibiting translation of Hk2 mRNA.
Our findings identify adipose HK2 as a critical mediator of systemic glucose homeostasis, and suggest that obesity-induced loss of adipose HK2 is an evolutionarily conserved, non-cell-autonomous mechanism for the development of hyperglycemia. 15 
One Sentence Summary:
Loss of the glycolytic enzyme Hexokinase 2 in adipose tissue is a mechanism underlying high blood glucose levels. phosphorylated glucose and thus a potential link of HK2 loss to hyperglycemia. HK2 is the most abundant (~80%) of the three hexokinase isoforms expressed in vWAT but the only one down-regulated upon HFD ( Fig. 1A and Fig. S2 ). Loss of HK2 was confirmed in vWAT and demonstrated in subcutaneous WAT (sWAT) and brown adipose tissue (BAT) of 4-week HFD mice by immunoblotting ( Fig. 1B) . Consistent with reduced HK2 5 expression, hexokinase activity was decreased in vWAT and sWAT (Fig. S3) . A longitudinal study of HFD-fed mice revealed that HK2 down-regulation in vWAT and sWAT occurred already at one week of HFD and correlated with hyperglycemia ( Fig. S4A-E). HK2 expression was unchanged in skeletal muscle ( Fig. 1B) , indicating that HFD decreases HK2 expression specifically in adipose tissue. Consistent with a 10 previous study (14) , expression of the glucose transporter GLUT4 was not affected in vWAT of 4-week HFD mice (Fig. 1A) . GLUT4 was down-regulated in sWAT after >2 weeks of HFD ( Fig. S4E) . Confirming earlier observations (14, 15) , insulin signaling, as determined by AKT phosphorylation at S473 (AKT-pS473), was normal at 4 weeks of HFD ( Fig. S4E) . Shifting the diet from HFD to ND for 2 weeks restored HK2 expression 15 and normal blood glucose levels ( Fig. 1C and Fig. S4D ), suggesting that loss of HK2 upon HFD is a transient physiological response. Furthermore, the finding that HK2 expression inversely correlated with hyperglycemia suggests that loss of adipose HK2 may be causal for loss of glucose homeostasis. Omental WAT (human vWAT) biopsies from obese non-diabetic and obese diabetic patients displayed reduced HK activity (Fig. 20 1D and Table S2 ), consistent with the previous observation that HK2 expression is decreased in adipose tissue of diabetic patients (16) . These findings suggest that HK2 down-regulation in adipose tissue is a key event, possibly causal, in obesity-induced insulin insensitivity and hyperglycemia in mouse and human.
Mexican cavefish (Astyanax mexicanus), also known as blind fish, are hyperglycemic compared to surface fish from which they are descended (17) ( Fig. 1E-F) . 5 Hyperglycemia, although a pathological condition in mouse and human, is a selected trait that allows cave-dwelling fish to survive in nutrient-limited conditions. Among three independently evolved cavefish isolates, Pachón and Tinaja cavefish (names refer to the caves from which the fish were isolated) contain a loss-of-function mutation in the insulin receptor, causing insulin resistance and hyperglycemia (17) (Fig. 1F) . The third 10 isolate, Molino cavefish, is the most hyperglycemic but contains a wild-type insulin receptor and displays normal insulin signaling (17). Since the phenotype of Molino fish is similar to that of HFD-fed mice, we hypothesized that this cavefish may be hyperglycemic due to a loss-of-function mutation in the hk2 gene. DNA sequencing of the hk2 gene of surface fish and the three cavefish variants revealed a mutation in the 15 hk2 gene uniquely in Molino. The homozygous, missense mutation in the coding region of the Molino hk2 gene changed highly conserved arginine 42 (R42) to histidine (R42H) ( Fig. 1G and Fig. S5A ). Based on the published structure of HK2 (18), R42 forms a salt bridge with aspartic acid 272 (D272) to stabilize the conformation of HK2 ( Fig. 1H) , predicting that R42H destabilizes HK2 and is thus a loss-of-function mutation. To test 20 this prediction, we over-expressed wild-type HK2 (HK-WT) and HK2 harboring the Molino mutation (HK2-R42H) in HEK293T cells which have low intrinsic hexokinase activity. HK2-R42H displayed ~50% lower hexokinase activity compared to HK2-WT, despite similar expression levels, suggesting that R42H is indeed a loss-of-function mutation ( Fig. 1I and Fig. S5B ). Thus, the R42H mutation may account for the hyperglycemia in Molino cavefish. In other words, R42H in Molino appears to be a genetically fixed version of what we observe in mice as a physiological down-regulation of HK2 in response to HFD. The findings in Molino provide orthogonal evidence that the 5 down-regulation of HK2 in mice is physiologically relevant.
The above findings altogether suggest that adipose-specific loss of HK2 may be a cause of insulin insensitivity and hyperglycemia. To test this hypothesis, we first generated a stable HK2 knockdown pre-adipocyte 3T3-L1 cell line ( Fig. S6A-B ). HK2 10 knockdown pre-adipocytes differentiated normally to produce mature adipocytes ( Fig.   S6C-D) . The glycolytic rate was lower in HK2 knockdown adipocytes compared to controls, as measured by extracellular acidification rate (ECAR) ( Fig. 2A ) and lactate production ( Fig. 2B) . Furthermore, although basal glucose uptake did not differ, insulinstimulated glucose uptake was 50% lower in HK2 knockdown adipocytes ( Fig. 2C) . 15 Thus, loss of HK2 causes insulin insensitivity in adipocytes in vitro.
To examine further the role of adipose HK2 in glucose homeostasis, and in particular the causality of HK2 loss in hyperglycemia, we generated an adipose-specific Hk2 knockout (AdHk2KO) mouse. In AdHk2KO mice, HK2 expression was decreased in vWAT, sWAT, and BAT but unchanged in skeletal muscle ( Fig. S7 and S8) , similar to 20 HFD-fed mice ( Fig. 1B) . AdHk2KO mice displayed slightly less fat mass and slightly more lean mass than controls, but no difference in overall body weight ( Fig. S9A-C ).
No significant difference was observed in organ weight, except for a small decrease in vWAT and a small increase in liver weight ( Fig. S9D-E) . Importantly, AdHk2KO mice were insulin insensitive and severely glucose intolerant ( Fig. 2D and 2E) . These findings indicate that loss of HK2 specifically in adipose tissue causes insulin insensitivity and hyperglycemia. 5 Adipose tissue accounts for only <5% of glucose disposal (3, 4). Thus, the severe glucose intolerance observed in AdHk2KO mice ( Fig. 2E ) cannot be explained solely by impaired glucose uptake into adipose tissue. Adiponectin and leptin, two well-known adipokines controlling systemic glucose homeostasis (19), were unchanged in AdHk2KO mice compared to controls ( Fig. S10A-E) . Another possible explanation for 10 the observed severity of glucose intolerance could be impaired insulin secretion.
However, plasma insulin levels were similar in AdHk2KO and control mice ( Fig. S11A-B ). Moreover, insulin signaling was not affected in adipose tissue, skeletal muscle, and liver of fasted and re-fed AdHk2KO mice ( Fig. S7, S8 , and S12A). These findings indicate that hyperglycemia in AdHk2KO mice is not due to defective adipokine 15 expression or insulin signaling.
Another potential explanation for the severity of glucose intolerance in AdHk2KO mice is de-repressed hepatic glucose production. Adipose tissue is known to impinge negatively on glucose production in liver (6, 9, 11, 20) , the main glucose producing organ. To examine whether AdHk2KO mice display enhanced hepatic glucose 20 production, we first performed a pyruvate tolerance test (PTT). AdHk2KO mice displayed significantly higher glucose production compared to controls (Fig. 3A) . We next examined expression of gluconeogenic genes (G6pc and Pepck) in liver.
Consistent with the observed increase in glucose production, gluconeogenic genes were upregulated in AdHk2KO liver ( Fig. 3B) . These findings suggest that enhanced hepatic gluconeogenesis accounts for the severity of glucose intolerance in AdHk2KO mice. Thus, loss of adipose HK2 non-cell-autonomously promotes hyperglycemia by enhancing hepatic gluconeogenesis. 5 We observed enhanced gluconeogenic capacity in AdHk2KO mice despite normal systemic insulin signaling, including in liver. To investigate this apparent contradiction, we examined lipogenic gene expression, another readout for hepatic insulin action. Sterol regulatory element-binding protein 1c (SREBP1c) is a transcription factor that activates lipogenic genes and thereby promotes de novo lipogenesis in the 10 liver (21). Expression of SREBP1c and its target fatty acid synthesis genes (Acly, Scd1, Fasn, and Acc) were increased in liver of AdHk2KO mice ( Fig. 3C) . FASN and ACC protein levels were also increased in liver of AdHk2KO mice (Fig. S12A) . These data further suggest that loss of adipose HK2 promotes hepatic lipogenesis. The increased hepatic gluconeogenic and lipogenic capacity observed in AdHk2KO mice mimics a 15 condition in diabetic patients known as selective insulin resistance (22) (see below).
Thus, loss of adipose HK2 causes selective insulin resistance and thereby contributes to the pathogenesis of type 2 diabetes.
We note that hepatic triglyceride (TG) levels were unchanged in AdHk2KO mice despite increased expression of lipogenic genes and proteins ( Fig. 3C and Fig. S12A -20 B). Most likely, de novo-synthesized TG in AdHk2KO liver is delivered to adipose tissue for storage. This is consistent with our observation that adipose tissue mass is largely unaffected in AdHk2KO mice.
How does loss of adipose HK2 increase hepatic gluconeogenesis? Adipose lipogenesis non-cell-autonomously inhibits hepatic glucose production (20, 23, 24). More specifically, adipose-specific knockout of the transcription factor carbohydrateresponsive element binding protein (ChREBP) decreases adipose lipogenesis and Consistent with the role of adipose lipogenesis in inhibiting hepatic gluconeogenesis, adipose lipolysis and consequential release of non-esterified fatty acid (NEFA) enhances glucose production in liver (23). Furthermore, in addition to activating lipogenic genes, ChREBP inhibits NEFA release (20). We examined the effect of HK2 loss on NEFA release. Glucose administration increased insulin levels in fasted AdHk2KO and control mice in a similar manner ( Fig. S11B) . However, this physiological increase in insulin levels inhibited NEFA release in control mice but not in AdHk2KO mice (Fig. 3F) . These findings combined with previous observations (11, 23, 5 24) suggest that loss of HK2 promotes release of NEFA which in turn de-represses hepatic gluconeogenesis. Thus, loss of adipose HK2 both prevents storage and promotes release of fatty acid that activates gluconeogenesis in the liver.
Our findings suggest that HFD causes loss of adipose HK2 and thereby triggers 10 hyperglycemia. How does HFD down-regulate adipose HK2? To answer this question, we first examined Hk2 mRNA expression in HFD-and ND-fed mice. HFD-fed mice exhibited decreased Hk2 mRNA in sWAT but not in vWAT or BAT (Fig. 4A ). This suggests that HK2 synthesis is down-regulated at the transcriptional level in sWAT, and at a post-transcriptional level in vWAT and BAT. To investigate the post-transcriptional 15 mechanism, we performed polysome profiling on vWAT from HFD-and ND-fed mice. In the presence of cycloheximide to maintain ribosome-mRNA complexes, vWAT lysates from HFD-fed mice contained more polysomes and fewer monosomes (80S ribosome) relative to ND-fed mice (Fig. 4B ). An increase in polysomes can be due to increased translation initiation or decreased elongation. To distinguish these two possibilities, we 20 performed polysome profiling in the absence of cycloheximide, a condition which allows actively translating ribosomes to run off mRNA. Although there were fewer overall polysomes in the absence of cycloheximide, we consistently observed more polysomes in vWAT from HFD-fed mice ( Fig. 4C ), suggesting that HFD inhibits or slows translation elongation of a subset of mRNA species. Shifting the diet from HFD to ND for 2 weeks restored elongation ( Fig. 4D) , as described above for glycemia ( Fig. S4D) . To determine whether HFD affects elongation of Hk2 mRNA translation in particular, we measured Hk2 mRNA in monosome, light polysome, and heavy polysome fractions.
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Hk2 mRNA from HFD vWAT was enriched in heavy polysomes, whereas it was enriched in light polysomes in ND vWAT ( Fig. 4E and Fig. S14A ). To further examine reduced HK2 protein synthesis, we measured synthesis of HK2 in vWAT of HFD-fed mice. vWAT explants from HFD-or ND-fed mice were treated with L-azidohomoalanine (AHA), a methionine analog, and AHA-containing polypeptides were purified and 10 quantified by mass spectrometry. The amount of AHA-containing HK2 polypeptides was significantly decreased in vWAT explants from HFD-fed mice (Fig. 4F) . Thus, HFD down-regulates HK2 in vWAT by inhibiting Hk2 mRNA translation.
It was recently reported that the forkhead transcription factors FOXK1 and FOXK2 promote Hk2 transcription in adipose tissue(28). We investigated whether the 15 transcriptional down-regulation of Hk2 mRNA in sWAT is due to loss of FOXK1 and FOXK2. Foxk1 and Foxk2 expression was significantly decreased in sWAT, but not in vWAT or BAT, of HFD-fed mice ( Fig. 4G and S14B-C). Thus, HFD appears to downregulate HK2 in sWAT by inhibiting FOXK1/2 and, thereby, expression of the Hk2 gene.
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How obesity causes hyperglycemia is a long-standing question. In this study, we show that a high fat diet causes hyperglycemia by inducing loss of HK2 specifically in adipose tissue. Loss of adipose HK2 leads to hyperglycemia in two ways ( Fig. 4H) . First, HK2 loss results in reduced glucose uptake by adipose tissue due to the inability of adipocytes to trap non-phosphorylated glucose. Second, loss of HK2 in adipocytes derepresses glucose production in liver.
In liver, insulin normally down-regulates gluconeogenesis to decrease blood glucose and up-regulates lipogenesis to increase energy storage. Paradoxically, in type 5 2 diabetes, insulin fails to inhibit gluconeogenesis but stimulates lipogenesis, hence the liver is selectively insulin resistant (22). Furthermore, previous findings suggest that selective resistance occurs despite intact hepatic insulin signaling (24). Consistent with these previous findings, we observed that loss of adipose HK2 causes selective insulin resistance without affecting systemic insulin signaling. Thus, we propose that loss of 10 adipose HK2 is a mechanism for selective insulin resistance and ultimately diabetes.
We found an HK2-R42H mutation in naturally hyperglycemic Mexican cavefish.
To date, no human monogenic disease has been reported associated with mutations in the HK2 gene. However, 12 R42W and 4 R42Q alleles are reported in the genomAD database(29). Further studies are required to determine whether these alleles are loss- 
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Materials and Methods: Mouse
Wild-type C57BL/6JRj mice were purchased from JANVIER LABS. Mice carrying Hk2 with exons 4-10 flanked by loxP sites (Hk2 fl/fl ) were as described (30). Adipoq-CreER T2 mice were provided by Prof. Stefan Offermanns (MPI-HLR, Germany) (31). Hk2 fl/fl mice were crossed with 5 Adipoq-CreER T2 mice, and resulting Cre positive Hk2 fl/+ mice were crossed with Hk2 fl/fl mice to generate adipocyte-specific Hk2 knockout (Adipoq-CreER T2 positive Hk2 fl/fl ) mice (AdHk2KO). Hk2 knockout was induced by i.p. injection of 1 mg/mouse tamoxifen (Sigma-Aldrich) in corn oil for 7 days. Littermate Cre negative animals were used as a control. Control mice were also treated with tamoxifen.
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Mice were housed at 22 ºC in a conventional facility with a 12 hour light/dark cycle with unlimited access to water, and normal diet (ND) or high fat diet (HFD: 60% kcal % fat NAFAG 2127, KLIBA). Only male mice between 6 and 17 weeks of age were used for experiments.
Plasmids 15
The R42H mutation was introduced into the pLenti-CMV-ratHK2 by PCR using the oligos 5'atttctaggcACttccggaaggagatggagaaag3' and 5'cttccggaaGTgcctagaaatctccagaagggtc3'. The desired sequence change was confirmed.
Cell culture
20
HEK293T cells were obtained from ATCC and cultured in M1 (DMEM supplemented with 4 mM glutamine, 1mM sodium pyruvate, 1x penicillin and streptomycin, and 10% FBS). 3T3-L1 cells were obtained from ATCC and cultured and differentiated as previously described(32). In brief, 3T3-L1 preadipocyte cells were maintained in M1 medium at 37 ºC incubator with 5% CO2. For differentiation, cells were maintained in M1 medium for 2 days after reaching confluence. The 25 cells were then transferred to M2 medium (M1 medium supplemented with 1.5 µg/mL insulin, 0.5 mM IBMX, 1 µM dexamethasone, and 2 µM rosiglitazone), defined as day 0 postdifferentiation. After 2 days, the cells were transferred to M3 medium (M1 with 1.5 µg/mL insulin). At day 4 post-differentiation, cells were transferred back to M2 medium. From day 6 post-differentiation, cells were maintained in M3 with medium change every two days. 
Human biopsies
Omental white adipose tissue (oWAT) biopsies were obtained from lean subjects with normal fasting glucose level and body mass index (BMI) < 27 kg/m 2 , from obese non-diabetic subjects 40 with BMI > 35 kg/m 2 HbA1c < 6.0%, and from obese diabetic sujects with BMI > 35 kg/m 2 HbA1c > 6.1% (Table S2 ). All subjects gave informed consent before the surgical procedure. Patients were fasted overnight and underwent general anesthesia. All oWAT specimens were obtained between 8:30 and 12:00am, snap-frozen in liquid nitrogen, and stored at -80 ºC for subsequent use.
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Proteomics
Tissues were pulverized and homogenized in lysis buffer containing 100 mM Tris-HCl pH7.5, 2 mM EDTA, 2 mM EGTA, 150 mM NaCl, 1% Triton X-100, cOmplete inhibitor cocktail (Roche) and PhosSTOP (Roche). Proteins were precipitated by trichloroacetic acid (Sigma) and the isobaric tandem mass tags (TMT 10-plex, Thermo Fisher Scientific) as described previously (34). Shortly, peptides were resuspended in 20 μl labeling buffer (2 M urea, 0.2 M HEPES, pH 8.3) and 5 μL of each TMT reagent were added to the individual peptide samples followed by a 1 h incubation at 25 °C. To control for ratio distortion during quantification, a peptide calibration mixture consisting of six digested standard proteins mixed in different amounts was added to 5 each sample before TMT labeling. To quench the labelling reaction, 1.5 μL aqueous 1.5 M hydroxylamine solution was added and samples were incubated for another 10 min at 25 °C followed by pooling of all samples. The pH of the sample pool was increased to 11.9 by adding 1 M phosphate buffer (pH 12) and incubated for 20 min at 25 °C to remove TMT labels linked to peptide hydroxyl groups. Subsequently, the reaction was stopped by adding 2 M hydrochloric 10 acid and until a pH < 2 was reached. Finally, peptide samples were further acidified using 5% TFA, desalted using Sep-Pak Vac 1cc (50 mg) C18 cartridges (Waters) according to the manufacturer's instructions and dried under vacuum.
TMT-labeled peptides were fractionated by high-pH reversed phase separation using a XBridge Peptide BEH C18 column (3,5 µm, 130 Å, 1 mm x 150 mm, Waters) on an Agilent 1260 15 Infinity HPLC system. Peptides were loaded on column in buffer A (20 mM ammonium formate in water, pH 10) and eluted using a two-step linear gradient from 2% to 10% in 5 minutes and then to 50% buffer B (20 mM ammonium formate in 90% acetonitrile, pH 10) over 55 min at a flow rate of 42 µl/min. Elution of peptides was monitored with a UV detector (215 nm, 254 nm) and a total of 36 fractions were collected, pooled into 12 fractions using a post-concatenation 20 strategy as previously described(35) and dried under vacuum.
Dried peptides were resuspended in 20 μl of 0.1% aqueous formic acid and subjected to LC-MS/MS analysis using a Q Exactive HF Mass Spectrometer fitted with an EASY-nLC 1000 (both Thermo Fisher Scientific) and a custom-made column heater set to 60 °C. Peptides were resolved using a RP-HPLC column (75 μm × 30 cm) packed in-house with C18 resin (ReproSil-25 Pur C18-AQ, 1.9 μm resin; Dr. Maisch GmbH) at a flow rate of 0.2 μL/min. The following gradient was used for peptide separation: from 5% B to 15% B over 10 min to 30% B over 60 min to 45 % B over 20 min to 95% B over 2 min followed by 18 min at 95% B. Buffer A was 0.1% formic acid in water and buffer B was 80% acetonitrile, 0.1% formic acid in water.
The mass spectrometer was operated in DDA mode with a total cycle time of 30 approximately 1 sec. Each MS1 scan was followed by high-collision-dissociation (HCD) of the 10 most abundant precursor ions with dynamic exclusion set to 30 sec. For MS1, 3e6 ions were accumulated in the Orbitrap over a maximum time of 100 ms and scanned at a resolution of 120,000 FWHM (at 200 m/z). MS2 scans were acquired at a target setting of 1e5 ions, accumulation time of 100 ms and a resolution of 30,000 FWHM (at 200 m/z). Singly charged 35 ions and ions with unassigned charge state were excluded from triggering MS2 events. The normalized collision energy was set to 35%, the mass isolation window was set to 1.1 m/z and one microscan was acquired for each spectrum. The acquired raw-files were converted to the mascot generic file (mgf) format using the msconvert tool (part of ProteoWizard, version 3.0.4624 (2013-6-3)). Using the MASCOT 40 algorithm (Matrix Science, Version 2.4.1), the mgf files were searched against a decoy database containing normal and reverse sequences of the predicted SwissProt entries of Mus musculus (www.ebi.ac.uk, release date 2014/11/24), the six calibration mix proteins(34) and commonly observed contaminants (in total 50214 sequences for Mus musculus) generated using the SequenceReverser tool from the MaxQuant software (Version 1.0.13.13). The precursor ion 45 tolerance was set to 10 ppm and fragment ion tolerance was set to 0.02 Da. The search criteria were set as follows: full tryptic specificity was required (cleavage after lysine or arginine residues unless followed by proline), 3 missed cleavages were allowed, carbamidomethylation (C) and TMT6plex (K and peptide N-terminus) were set as fixed modification and oxidation (M) as a variable modification. Next, the database search results were imported into the Scaffold Q+ 50 software (version 4.3.2, Proteome Software Inc., Portland, OR) and the protein false identification rate was set to 1% based on the number of decoy hits. Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were grouped into clusters. Acquired reporter ion intensities in the experiments were employed for automated quantification and statically analysis using a modified version of our in-house developed SafeQuant R script(34). This analysis included adjustment of reporter ion intensities, global data normalization by equalizing the total reporter ion intensity across all channels, summation of reporter ion intensities per protein and channel, calculation of protein abundance ratios and testing for differential abundance using empirical Bayes moderated t-statistics. Finally, the calculated p-values were corrected for multiple testing using the 10 Benjamini−Hochberg method (q-value). Deregulated proteins were selected by log2(fold change) > 0.6 or log2(fold change) < -0.6, q-value < 0.01.
Immunoblots
Adipose tissue, liver, and skeletal muscle were homogenized in lysis buffer containing 100 mM 15 Tris-HCl pH7.5, 2 mM EDTA, 2 mM EGTA, 150 mM NaCl, 1% Triton X-100, cOmplete inhibitor cocktail (Roche) and PhosSTOP (Roche). Protein concentration was determined by the Bradford assay, and equal amounts of protein were separated by SDS-PAGE, and transferred onto nitrocellulose membranes (GE Healthcare). Antibodies used in this study were as follows: AKT (Cat#4685 or Cat#2920), AKT-pS473 (Cat#4060), AKT-pT308 (Cat#13038), PRAS40- 
RNA isolation and quantitative RT-PCR
Total RNA was isolated with TRIzol reagent (Sigma-Aldrich) and RNeasy kit (Qiagen). RNA was reverse-transcribed to cDNA using iScript cDNA synthesis kit (BIO-RAD). Semiquantitative 30 real-time PCR analysis was performed using fast SYBR green (Applied Biosystems). Relative expression levels were determined by normalizing each CT values to Tbp using the ∆∆CT method. The sequence for the primers used in this study was as follows. Fasn-fw: 5'GCTGCGGAAACTTCAGGAAAT3', Fasn-rv: 5'AGAGACGTGTCACTCCTGGACTT3', Acc-fw: 5'AAGGCTATGTGAAGGATG3', Acc-rv: 5'CTGTCTGAAGAGGTTAGG3', Cd36-fw: 5' 35 TGGCCTTACTTGGGATTGG3', Cd36-rv: 5' CCAGTGTATATGTAGGCTCATCCA 3', G6pc-fw: 5'CCATGCAAAGGACTAGGAACAA3', G6pc-rv: 5' TACCAGGGCCGATGTCAAC 3', Pepck-fw: 5' CCACAGCTGGTGCAGAACA3', Pepck-rv: 5' GAAGGGTCGATGGCAAA 3', Chrebp-fw: 5'CACTCAGGGAATACACGCCTAC3', Chrebp-rv: 5'ATCTTGGTCTTAGGGTCTTCAGG3', Chrebp-alpha-fw: 5'CGACACTCACCCACCTCTTC3', Chrebp-alpha-rv: 40 5'TTGTTCAGCCGGATCTTGTC3', Chrebp-beta-fw: 5'TCTGCAGATCGCGTGGAG3', Chrebpbeta-rv: 5'CTTGTCCCGGCATAGCAAC3', Hk2-fw: 5' ACGGAGCTCAACCAAAACCA3', Hk2-rv: 5'TCCGGAACCGCCTAGAAATC3', Foxk1-fw: 5' GGCTGTCACTCAGAATGGAA3', Foxk1-rv: 5'GAGGCAGATGTGGTAGTGGAG3', Foxk2-fw: 5' CCACGGGAACTATCAGTGCT3' , Foxk2rv: 5' GTCATCCTTTGGGCTGTCTC3', Lep-fw: 5' TCACACACGCAGTCGGTATC, Lep-rv:
Measurements were performed with a hexokinase assay kit (abcam) following manufacturer's instructions.
Seahorse analyses
Measurements were performed with an XF96 Extracellular Flux Analyzer (Seahorse Bioscience 5 of Agilent) following manufacturer's instructions.
Lactate measurement
Differentiated adipocytes were starved serum overnight and stimulated with 100 nM insulin for 2 hours. Extracellular lactate was measured with the Lactate Pro 2 analyzer (Axonlab). 
Insulin tolerance test, glucose tolerance test, pyruvate tolerance test 20
For the insulin and glucose tolerance tests, mice were fasted for 6 hours and insulin Humalog (Lilly, i.p. 0.75 or 0.5 U/kg body weight) or glucose (2 g/kg body weight) was given, respectively. For the pyruvate tolerance test, mice were fasted for 15 hours and pyruvate (2 g/kg body weight) was administered. Blood glucose was measured with a blood glucose meter (Accu-Check).
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Polysome profile analyses
Tissues were homogenized in polysome lysis buffer (10 mM Tris-HCl, pH7.5, 140 mM KCl, 5 mM MgCl2, 1mM DTT, 0.5% Triton x-100, 0.05% sodium deoxycholate, 40 u/mL RNase inhibitor) in the presence or absence of 100 µg/mL cycloheximide and the lysates were 30 centrifuged twice at 14,000 g for 10 min. The cleared lysates were loaded onto 5-50% sucrose gradients (10 mM Tris-HCl, pH7.5, 140 mM KCl, 5 mM MgCl2, 5% or 50% sucrose) and centrifuged with TH-641 (Thermo Scientific) at 36,000 rpm for 2 hours at 4 ºC. Fractions were collected by a Gradient Station (BIOCOMP INSTRUMENTS) with continuous recording of optical density (OD) at 254 nm. RNA from each fraction was isolated with TRIzol and qRT-PCR 35 were performed as described(36).
AHA-incorporation
vWATs from ND-or HFD-fed mice were immediately incubated in low glucose DMEM containing 50 µM azidohomoalanine (AHA) for 30. The tissues were powdered, lysed by bio-40 rupture and clarified by centrifugation at 15,000 g for 15 min twice. The 100 µg proteins were used for CLICK reaction following manufacturer's instructions. The biotinylated proteins were pulled-down using streptavidin magnetic beads for 2 hours at 4 ºC. The pulled-down proteins were digested with trypsin. The digested peptides were acidified using 5 % TFA and desalted using C18 columns. The eluted peptides were dried and analyzed by mass spectrometry.
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Insulin ELISA Plasma insulin levels were measured by ultrasensitive mouse insulin ELISA kit (Crystal Chem) according to the manufacturer's instructions.
Plasma Leptin levels were measured by mouse mouse Leptin ELISA kit (Crystal Chem) according to the manufacturer's instructions.
Adiponectin ELISA
Plasma Adiponectin levels were measured by mouse mouse Adiponectin ELISA kit (Crystal 5 Chem) according to the manufacturer's instructions.
Hepatic triglyceride measurement
Hepatic triglyceride levels were measured using a triglyceride assay kit (Abcam) according to the manufacturer's instructions.
Body composition measurement
Body composition was measured by nuclear magnetic resonance imaging (Echo Medical Systems).
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Study Approval
All animal experiments were performed in accordance with federal guidelines for animal experimentation and were approved by the Kantonales Veterinäramt of the Kanton Basel-Stadt. For human biopsies, the study protocol was approved by the Ethikkomission Nordwest-und Zentralschweiz (EKNZ).
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Statistics
Sample size was chosen according to our previous studies and published reports in which similar experimental procedures were described. The investigators were not blinded to the treatment groups. All data are shown as the mean ± SEM. Sample numbers are indicated in 25 each figure legend. For mouse experiments, n represents the number of animals, and for cell culture experiments, N indicates the number of independent experiments. To determine the statistical significance between 2 groups, an unpaired two-tailed Student's t test was performed. For more than 3 groups, one-way ANOVA was performed. For ITT, GTT, PTT, weigh curve data, two-way ANOVA was performed. All statistical analysis was performed using GraphPad Fig. S2. HK2 is the most abundant hexokinase in vWAT. 5 Protein expression of HK1, HK2, and HK3 in vWAT of C57BL/6 mice (Table S1 ) was normalized to HK1 expression. n=5. One-way ANOVA compared to 0-week HFD-fed mice, **p<0.01, ***p<0.001, ****p<0.0001. n=10. (C) Fasting insulin levels of mice fed an HFD for 0, 1, 2, or 4 weeks. One-way ANOVA compared to 0-week HFD-fed mice, *p<0.05. n=5.
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(D) ITT on mice fed a HFD for 0, 1, 2, 4 weeks, and mice fed 2-week HFD and 2-week ND. Mice were fasted for 6 hours and injected with insulin (0.75 U/kg body weight). Two-way ANOVA, *p<0.05. n=10 (0-week ND), 10 (1-week HFD), 10 (2-week HFD), 10 (2-week HFD), and 6 (2-week HFD + 2-week ND). Table S1 . Proteome data for vWAT of ND-or 4-week HFD-fed C57BL/6JRj mice. A. Total proteome in vWAT B. Deregulated proteome in vWAT. 5   Table S2 . Clinical data for patients.
